We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,056.35 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 01:00:00 |
From Jul 2019 to Jul 2024
By Maria Armental
U.S. health regulators have approved Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA's (SNY) blockbuster drug Dupixent (dupilumab) to treat asthma.
Dupixent, which already was approved to treat eczema, is part of a new generation of asthma treatments that are given by injection rather than inhaled, and that act on an underlying cause of asthma rather than treating the symptoms.
Dupixent has been approved as an add-on maintenance therapy in patients age 12 years and older with moderate-to-severe asthma.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
October 19, 2018 18:37 ET (22:37 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
